Quarterly report pursuant to Section 13 or 15(d)

Share-based Payments

v3.19.1
Share-based Payments
3 Months Ended
Mar. 31, 2019
Share-based Payment Arrangement [Abstract]  
Share-based Payments

Note 6 - Share-based Payments

 

Equity incentive Plans

 

2013 Stock Incentive Plan

 

On January 23, 2014, the Company adopted the 2013 Stock Incentive Plan (“2013 Plan”). The 2013 Plan was amended by the Board on January 9, 2015 and September 30, 2016, and such amendments were ratified by shareholders on December 7, 2018. The 2013 Plan provides for the issuance of up to 103,750 shares of the Company’s common stock. As of March 31, 2019, grants of restricted stock and options to purchase 74,403 shares of Common Stock have been issued pursuant to the 2013 Plan, and 29,347 shares of Common Stock remain available for issuance.

 

2017 Stock Incentive Plan

 

On August 7, 2017, the shareholders approved and the Company adopted the 2017 Stock Incentive Plan (“2017 Plan”). The 2017 Plan provides for the issuance of up to 168,750 shares of the Company’s common stock. As of March 31, 2019, grants of restricted stock and options to purchase 51,032 shares of Common Stock have been issued pursuant to the 2017 Plan, and 117,718 shares of Common Stock remain available for issuance.

 

2018 Stock Incentive Plan

 

On December 7, 2018, the shareholders approved and the Company adopted the 2018 Stock Incentive Plan (“2018 Plan”). The 2018 Plan provides for the issuance of up to 1,875,000 shares of the Company’s common stock. As of March 31, 2019, grants of RSUs to purchase 374,481 shares of Common Stock have been issued pursuant to the 2018 Plan, and 1,500,519 shares of Common Stock remain available for issuance.

 

Stock Options

 

The following table summarizes the option activities for the three months ended March 31, 2019:

 

                      Weighted        
          Weighted     Weighted     Average        
          Average     Average     Remaining     Aggregate  
    Number of     Exercise     Grant Date     Contractual     Intrinsic  
    Shares     Price     Fair Value     Term (years)     Value  
Balance at December 31, 2018     10,502     $ 30.41     $ 17.42       1.43     $         -  
Granted     -       -       -       -       -  
Exercised     -       -       -       -       -  
Forfeited     (3,625 )     29.02       22.40       -       -  
Canceled/Expired     -       -       -       -       -  
Balance at March 31, 2019     6,877     $ 31.14     $ 14.80       1.14     $ -  
Exercisable as of March 31, 2019     6,877     $ 31.14     $ 14.80       1.14     $ -  

 

The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying awards and the closing stock price of $0.97 for the Company’s common shares on March 31, 2019.

 

As of March 31, 2019, all of the Company’s outstanding stock options were fully vested and exercisable.

 

During the three months ended March 31, 2019 and 2018, the Company incurred stock option expenses totaling $0 and $2,712, respectively.

 

Restricted Stock Units

 

On March 29, 2019, the Compensation Committee of the Board of Directors approved the grant of 124,827 Restricted Stock Units (“RSU”) to each of the three directors. Each RSU had a grant date fair value of $0.97 which shall be amortized on a straight-line basis over the vesting period into administrative expenses within the Condensed Consolidated Statement of Operations and Comprehensive Loss. Such RSUs were granted under the 2018 Plan, and shall vest on January 1, 2020, with vesting accelerated upon a change of control. Upon vesting, such RSUs are settled with the issuance of common stock, including on a net of tax basis, at the discretion of the holder.

 

At March 31, 2019, the unamortized value of the RSU’s was $359,341. The unamortized amount will be expensed over a weighted average period of 10 months. A summary of activity related to RSUs for the three months ended March 31, 2019 is presented below:

 

          Weighted  
          Average  
    Number of     Grant Date  
    RSUs     Fair Value  
Balance at December 31, 2018     -     $ -  
Granted     374,481     $ 0.97  
Exercised     -       -  
Forfeited     -       -  
Canceled/Expired     -       -  
Balance at March 31, 2019     374,481     $ 0.97  
Exercisable as of March 31, 2019     -       -  

 

During the three months ended March 31, 2019, the Company incurred RSU expense of $3,906.

 

Stock Warrants

 

The table below summarizes the warrant activity for the year ended March 31, 2019:

 

          Weighted     Average        
          Average     Remaining     Aggregate  
    Number of     Exercise     Contractual     Intrinsic  
    Warrants     Price     Term (years)     Value  
Balance at December 31, 2018     2,110,737     $ 3.10       4.21     $          -  
Granted     -       -       -       -  
Exercised     -       -       -       -  
Forfeited     -       -       -       -  
Canceled/Expired     -             -       -       -  
Balance at March 31, 2019     2,110,737     $ 3.10       3.96     $ -  
Exercisable as of March 31, 2019     2,110,737     $ 3.10       3.96     $ -  


 

The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying awards and the closing stock price of $0.97 for the Company’s common shares on March 31, 2019. All warrants were vested on date of grant.